MidEuropa has agreed to sell Optegra, a leading European ophthalmology platform, to EssilorLuxottica. The deal, subject to regulatory approval, is expected to close later this year.

Optegra operates over 70 eye hospitals and diagnostic centres across Europe, offering both medically necessary and elective vision treatments. Since acquiring the company in 2023, MidEuropa has driven Optegra’s growth through eight add-on acquisitions across five countries, as well as greenfield expansion into the UK, Slovakia – where it became market leader – and the Netherlands.

MidEuropa’s support enabled Optegra to integrate AI-driven tools for streamlining cataract referrals and post-operative care, strengthening its operational model and market position. Under MidEuropa’s ownership, Optegra has solidified its role as a leading pan-European ophthalmology platform.

Pawel Malicki, Partner at MidEuropa, said the transaction opens “an exciting new chapter in Optegra’s evolution,” while Robert Knorr, Managing Partner, praised the team’s collaborative efforts in scaling the business through innovation and technology. Dr. Peter Byloos, CEO of Optegra, added that the partnership with EssilorLuxottica will allow Optegra to deliver more advanced, integrated eye care solutions across Europe.

MidEuropa’s exit from Optegra follows a string of recent healthcare divestments, including the sale of Regina Maria Group to Mehiläinen and the IPO of Diagnostyka. These exits are expected to deliver record proceeds to MidEuropa’s investors.

Advisers on the transaction included Houlihan Lokey (financial), White & Case (legal), PwC (financial and tax), and LEK and Mansfield Advisors (commercial). The MidEuropa team was led by Eugeniu Prodan, David Nemcek, and Ivo Cavrak.

If you think we missed any important news, please do not hesitate to contact us at news@pe-insights.com. 

Can`t stop reading? Read more.